Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07DCG
|
|||
| Drug Name |
Ivosidenib
|
|||
| Synonyms |
UNII-Q2PCN8MAM6; Q2PCN8MAM6; Ivosidenib [INN]; Ivosidenib [USAN]; Ivosidenib [WHO-DD]; GTPL9217; SCHEMBL15122512; EX-A992; MolPort-044-560-317; RG120; s8206; 1448347-49-6 (Ivosidenib); AKOS028113340; ZINC205136523; CS-5122; AS-35058; HY-18767
Click to Show/Hide
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Approved | [1], [2] | |
| Cholangiocarcinoma [ICD-11: 2C12.10; ICD-10: C22.1] | Phase 3 | [3] | ||
| Haematological malignancy [ICD-11: 2B33.Y] | Phase 1 | [4] | ||
| Company |
Agios Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C28H22ClF3N6O3
|
|||
| Canonical SMILES |
C1CC(=O)N(C1C(=O)N(C2=CC(=CN=C2)F)C(C3=CC=CC=C3Cl)C(=O)NC4CC(C4)(F)F)C5=NC=CC(=C5)C#N
|
|||
| InChI |
1S/C28H22ClF3N6O3/c29-21-4-2-1-3-20(21)25(26(40)36-18-11-28(31,32)12-18)37(19-10-17(30)14-34-15-19)27(41)22-5-6-24(39)38(22)23-9-16(13-33)7-8-35-23/h1-4,7-10,14-15,18,22,25H,5-6,11-12H2,(H,36,40)/t22-,25-/m0/s1
|
|||
| InChIKey |
WIJZXSAJMHAVGX-DHLKQENFSA-N
|
|||
| CAS Number |
CAS 1448347-49-6
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:145430
|
|||
| ADReCS Drug ID | BADD_D02524 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Oxalosuccinate decarboxylase (IDH1) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Citrate cycle (TCA cycle) | |||
| Glutathione metabolism | ||||
| Metabolic pathways | ||||
| Biosynthesis of antibiotics | ||||
| Carbon metabolism | ||||
| 2-Oxocarboxylic acid metabolism | ||||
| Biosynthesis of amino acids | ||||
| Peroxisome | ||||
| Central carbon metabolism in cancer | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| Pathwhiz Pathway | Warburg Effect | |||
| WikiPathways | TCA Cycle and PDHc | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| Peroxisomal lipid metabolism | ||||
| Glutathione metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT02989857) Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (ClarIDHy). U.S. National Institutes of Health. | |||
| REF 4 | ClinicalTrials.gov (NCT02073994) Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.